Complications of Diabetes Therapy

被引：24

作者：

Corathers, Sarah D. ^{[1
,2
]}

Peavie, Shawn ^{[2
]}

Salehi, Marzieh ^{[2
]}

机构：

[1] Cincinnati Childrens Hosp Med Ctr, Div Endocrinol, Cincinnati, OH 45229 USA

[2] Univ Cincinnati, Med Ctr, Div Endocrinol, Cincinnati, OH 45229 USA

来源：

ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA | 2013年 / 42卷 / 04期

关键词：

Diabetes; Treatment complications; Cardiovascular outcomes; beta-cell function; GLUCAGON-LIKE PEPTIDE-1; PEPTIDASE-4 INHIBITOR SITAGLIPTIN; IMPAIRED GLUCOSE-TOLERANCE; BETA-CELL FUNCTION; 10-YEAR FOLLOW-UP; GLYCEMIC CONTROL; OPEN-LABEL; DOUBLE-BLIND; EUROPEAN-ASSOCIATION; EXENATIDE EXENDIN-4;

D O I：

10.1016/j.ecl.2013.06.005

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Current strategies for the treatment of type 2 diabetes mellitus promote individualized plans to achieve target glucose levels on a patient-by-patient basis while minimizing treatment related risks. Maintaining glycemic control over time is a significant challenge because of the progressive nature of diabetes as a result of declining beta-cell function. This article identifies complications of non-insulin treatments for diabetes. The major classes of medications are reviewed with special focus on target population, mechanism of action, effect on weight, cardiovascular outcomes and additional class-specific side effects including effects on bone. Effects on beta-cell function are also highlighted.

引用

页码：947 / +

页数：25

共 151 条

[1]

Adeghate Ernest, 2011, Open Med Chem J, V5, P78, DOI 10.2174/1874104501105010078

[2] CLONING OF THE BETA-CELL HIGH-AFFINITY SULFONYLUREA RECEPTOR - A REGULATOR OF INSULIN-SECRETION [J].

AGUILARBRYAN, L ;

NICHOLS, CG ;

WECHSLER, SW ;

CLEMENT, JP ;

BOYD, AE ;

GONZALEZ, G ;

HERRERASOSA, H ;

NGUY, K ;

BRYAN, J ;

NELSON, DA .

SCIENCE, 1995, 268 (5209) :423-426

[3] PPARγ signaling and metabolism: the good, the bad and the future [J].

Ahmadian, Maryam ;

Suh, Jae Myoung ;

Hah, Nasun ;

Liddle, Christopher ;

Atkins, Annette R. ;

Downes, Michael ;

Evans, Ronald M. .

NATURE MEDICINE, 2013, 19 (05) :557-566

[4]

[Anonymous], DIABETES CARE

[5] Efficacy of GLP-1 Receptor Agonists and DPP-4 Inhibitors: Meta-Analysis and Systematic Review [J].

Aroda, Vanita R. ;

Henry, Robert R. ;

Han, Jenny ;

Huang, Wenying ;

DeYoung, Mary Beth ;

Darsow, Tamara ;

Hoogwerf, Byron J. .

CLINICAL THERAPEUTICS, 2012, 34 (06) :1247-1258

[6] Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes [J].

Aschner, Pablo ;

Kipnes, Mark S. ;

Lunceford, Jared K. ;

Sanchez, Matilde ;

Mickel, Carolyn ;

Williams-Herman, Debora E. .

DIABETES CARE, 2006, 29 (12) :2632-2637

[7] Pharmacology of Dipeptidyl Peptidase-4 Inhibitors Similarities and Differences [J].

Baetta, Roberta ;

Corsini, Alberto .

DRUGS, 2011, 71 (11) :1441-1467

[8] Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial [J].

Bailey, Clifford J. ;

Gross, Jorge L. ;

Hennicken, Delphine ;

Iqbal, Nayyar ;

Mansfield, Traci A. ;

List, James F. .

BMC MEDICINE, 2013, 11

[9] Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial [J].

Bailey, Clifford J. ;

Gross, Jorge L. ;

Pieters, Anne ;

Bastien, Arnaud ;

List, James F. .

LANCET, 2010, 375 (9733) :2223-2233

[10] Metformin in Cancer Therapy: A New Perspective for an Old Antidiabetic Drug? [J].

Ben Sahra, Issam ;

Le Marchand-Brustel, Yannick ;

Tanti, Jean-Francois ;

Bost, Frederic .

MOLECULAR CANCER THERAPEUTICS, 2010, 9 (05) :1092-1099

← 1 2 3 4 5 6 7 8 9 10 →